NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2006 (First half of fiscal year 2007)
Business Overview: NAI operates in two primary segments: Private Label Contract Manufacturing (providing manufacturing services for nutritional supplements) and Branded Products (marketing and distributing its own and third-party brands, including the Real Health Laboratories acquisition). The company is headquartered in San Marcos, California, with significant operations in Europe (NAIE).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 18% year-over-year. Private label contract manufacturing sales grew 10%, while branded products sales surged 79% primarily due to the inclusion of Real Health Laboratories (RHL) operations.
• Margin Expansion: Gross profit margin improved by 3.1 percentage points to 22.8%, driven by RHL operations, a favorable shift in sales mix, and reduced overhead expenses.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 40% to $9.42 million, largely attributed to incremental costs associated with the RHL acquisition.
• Interest Expense: Interest expense rose significantly ($256,000 increase year-to-date) due to a $3.8 million term loan obtained to fund the RHL acquisition and higher utilization of the line of credit.
• Cash Flow: Net cash provided by operating activities more than doubled to $9.64 million, driven by a $8.21 million reduction in accounts receivable (collections of record Q4 sales from the prior year).
• Debt Reduction: Total consolidated debt decreased from $15.9 million (June 30, 2006) to $7.5 million (Dec 31, 2006) due to significant payments on the working capital line of credit.

Guidance, Outlook, and Risks

• Strategic Focus: Management plans to leverage certified facilities to attract new private label customers, expand branded product marketing through RHL channels, and pursue further acquisitions to diversify revenue.
• Customer Concentration Risk: The company remains highly dependent on two major private label customers, who accounted for 71% of total net sales for the six months ended Dec 31, 2006 (down from 79% in the prior year). Loss of these customers would have a material adverse impact.
• Supplier Concentration: Raw material purchases are concentrated among a limited number of suppliers; three suppliers accounted for 36% of total raw material purchases.
• Foreign Exchange: The company is exposed to currency fluctuations (Euro and Swiss Franc). A 10% adverse change in exchange rates would have decreased net income by $201,000 for the period. The company utilizes option contracts to hedge these risks.
• Legal Proceedings: No material pending legal proceedings as of January 30, 2007.

Investor Verification Checklist

• Customer Dependency: Verify the stability of contracts with the top two private label customers (Customer 1 and Customer 2), which represent over 70% of revenue.
• RHL Integration: Assess the realization of anticipated cost savings and synergies from the integration of RHL and the Dr. Cherry Pathway to Healing product line.
• Debt Covenants: Review the amended credit facility terms, specifically the total liabilities to tangible net worth covenant (1.25/1.0) and fixed charge coverage ratio requirements.
• Inventory Levels: Monitor inventory balances ($17.5 million) relative to sales velocity, particularly for the branded products segment.
• Foreign Currency Hedging: Evaluate the effectiveness of current option contracts in mitigating exposure to the Euro and Swiss Franc.